Montane J, Bischoff L, Soukhatcheva G, Dai DL, Hardenberg G, Levings MK, Orban PC, Kieffer TJ, Tan R, Verchere CB.: Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets. J Clin Invest. 2011 Jul 1. pii: 43048. doi: 10.1172/JCI43048. [Epub ahead of print] PMID: 21737880
Wang X, Hao J, Metzger DL, Mui A, Ao Z, Verchere CB, Chen L, Ou D, Warnock GL.: Local expression of b7-h4 by recombinant adenovirus transduction in mouse islets prolongs allograft survival. Transplantation. 2009 Feb 27;87(4):482-90.
Warnock GL, Thompson DM, Meloche RM, Shapiro RJ, Ao Z, Keown P, Johnson JD, Verchere CB, Partovi N, Begg IS, Fung M, Kozak SE, Tong SO, Alghofaili KM, Harris C.: A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation. 2008 Dec 27;86(12):1762-6.
Marzban L, Tomas A, Becker TC, Rosenberg L, Oberholzer J, Fraser PE, Halban PA, Verchere CB.: Small interfering RNA-mediated suppression of proislet amyloid polypeptide expression inhibits islet amyloid formation and enhances survival of human islets in culture. Diabetes. 2008 Nov;57(11):3045-55.
Meng F, Marek P, Potter KJ, Verchere CB, Raleigh DP.: Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: implications for mechanistic studies of beta-cell death. Biochemistry. 2008 Jun 3;47(22):6016-24.
Trudeau JD, Kelly-Smith C, Verchere CB, Elliott JF, Dutz JP, Finegood DT, Santamaria P, Tan R: Prediction of spontaneous autoimmune diabetes by quantification of autoreactive T cells in peripheral blood. J Clin Invest 111:217-23, 2003.
Vidal J, Verchere CB, Andrikopoulos S, Wang F, Hull RL, Cnop M, Olin KL, LeBoeuf RC, O'Brien KD, Chait A, Kahn SE: The effect of apolipoprotein E deficiency on islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Diabetologia 46:71-79, 2003.
Wang J, Xu J, Finnerty J, Furuta M, Steiner DF, Verchere CB: The prohormone convertase enzyme 2 (PC2) is essential for processing of pro-islet amyloid polypeptide at the N-terminal cleavage site. Diabetes 50:534-539, 2001.
Park K, Verchere CB Identification of a heparin-binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide: implications for islet amyloid formation. J Biol Chem 276:16611-16616, 2001.
Verchere CB, D'Alessio DA, Prigeon RL, Hull RL, Kahn SE: The constitutive secretory pathway is a major route for islet amyloid polypeptide release in neonatal but not adult rat islet cells. Diabetes 49:1477-1484, 2000.
Kahn SE, Andrikopoulos S, Verchere CB: Islet amyloid: a long recognized but under appreciated pathology of type 2 diabetes mellitus. Diabetes 48:241-253, 1999.
Irminger J-C, Verchere CB, Meyer K, Halban PA: Proinsulin targeting to the regulated pathway is not impaired in carboxypeptidase E-deficient Cpefat/Cpefat mice. J Biol Chem 272:27532-27534, 1997.
Deeg M, Verchere CB: Regulation of GPI-specific phospholipase D secretion from beta TC3 cells. Endocrinology 138: 819-826, 1997.
Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE: Islet amyloid formation associated with hyperglycemia in transgenic mice with beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492-3496, 1996.
Verchere CB, Paoletta M, Neerman-Arbez M, Rose K, Gingerich RL, Kahn SE, Halban PA: Des-(27-31)C-peptide: a novel secretory product of the rat pancreatic beta cell produced by truncation of proinsulin connecting peptide in secretory granules. J Biol Chem 271:27475-27481,1996.